文献速递肿瘤 PET/CT核素与放射性配体治疗

124I/131I-CLR1404 在小儿实体瘤鼠异种移植模型中的临床前药代动力学与剂量学研究

Preclinical Pharmacokinetics and Dosimetry Studies of 124I/131I-CLR1404 for Treatment of Pediatric Solid Tumors in Murine Xenograft Models.
PubMed 文献 · J Nucl Med · 2019-03-29

研究在神经母细胞瘤、横纹肌肉瘤和尤文肉瘤小鼠异种移植模型中评估 124I-CLR1404 的体内药代动力学,并利用 Geant4 蒙特卡洛模拟估算 131I-CLR1404 分子放疗的肿瘤剂量学。结果显示 CLR 124 在各模型中均呈选择性摄取和 prolonged 滞留,肿瘤剂量与 131I-CLR1404 治疗后的肿瘤生长延迟相关,且峰值摄取平均比 124I-MIBG 高 22%。

要点

  • CLR 124 在小儿实体瘤异种移植模型中显示选择性摄取和 prolonged 滞留。
  • CLR 131 的个体化肿瘤剂量与治疗后肿瘤生长延迟呈相关性。
  • 在 MIBG 阳性神经母细胞瘤模型中,CLR 124 峰值摄取平均比 124I-MIBG 高 22%。

核心结论

  • CLR1404 是适合用于剂量学和治疗的治疗诊断支架,在小儿肿瘤学中具有潜在广泛适用性。
  • 鉴于 CLR 131 在成人中正在开展临床试验,这些数据支持开展小儿临床试验并提供详细剂量学以改进分子放疗治疗计划。

研究设计与样本

  • 研究在神经母细胞瘤、横纹肌肉瘤和尤文肉瘤的小鼠异种移植模型中进行。
  • 荷瘤小鼠接受小动物 PET/CT 成像以评估 CLR 124 的全身分布,并校正放射性衰变差异预测 CLR 131 的分布。
  • 代表 CLR 131 的图像体积用于 Geant4 蒙特卡洛模拟,计算 CLR 131 分子放疗的个体化肿瘤剂量学。
  • CLR 131 的药代动力学外推至成人和小儿人类以估算正常组织剂量学。
  • 在 MIBG 阳性神经母细胞瘤模型中直接比较 CLR 124 与 124I-MIBG。

主要发现

  • CLR 124 在所有研究的小儿实体瘤模型中显示选择性摄取和 prolonged 滞留。
  • CLR 131 分子放疗的个体化肿瘤剂量学与 CLR 131 分子放疗后的肿瘤生长延迟呈相关性。
  • 在 MIBG 阳性神经母细胞瘤模型中,CLR 124 的峰值摄取平均比 124I-MIBG 高 22%。

临床怎么用

  • CLR1404 可作为治疗诊断支架用于小儿实体瘤的剂量学评估和分子放疗。
  • 临床前剂量学数据可能有助于改进小儿分子放疗的治疗计划。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer is the second leading cause of death for children between the ages of 5 and 14 y. For children diagnosed with metastatic or recurrent solid tumors, for which the utility of external-beam radiotherapy is limited, the prognosis is particularly poor. The availability of tumor-targeting radiopharmaceuticals for molecular radiotherapy (MRT) has demonstrated improved outcomes in these patient populations, but options are nonexistent or limited for most pediatric solid tumors. 18-(p-iodophenyl)octadecylphosphocholine (CLR1404) is a novel antitumor alkyl phospholipid ether analog that broadly targets cancer cells. In this study, we evaluated the in vivo pharmacokinetics of 124I-CLR1404 (CLR 124) and estimated theranostic dosimetry for 131I-CLR1404 (CLR 131) MRT in murine xenograft models of the pediatric solid tumors neuroblastoma, rhabdomyosarcoma, and Ewing sarcoma. Methods: Tumor-bearing mice were imaged with small-animal PET/CT to evaluate the whole-body distribution of CLR 124 and, correcting for differences in radioactive decay, predict that of CLR 131. Image volumes representing CLR 131 provided input for Geant4 Monte Carlo simulations to calculate subject-specific tumor dosimetry for CLR 131 MRT. Pharmacokinetics for CLR 131 were extrapolated to adult and pediatric humans to estimate normal-tissue dosimetry. In neuroblastoma, a direct comparison of CLR 124 with 124I-metaiodobenzylguanidine (124I-MIBG) in an MIBG-avid model was performed. Results: In vivo pharmacokinetics of CLR 124 showed selective uptake and prolonged retention across all pediatric solid tumor models investigated. Subject-specific tumor dosimetry for CLR 131 MRT presents a correlative relationship with tumor-growth delay after CLR 131 MRT. Peak uptake of CLR 124 was, on average, 22% higher than that of 124I-MIBG in an MIBG-avid neuroblastoma model. Conclusion: CLR1404 is a suitable theranostic scaffold for dosimetry and therapy with potentially broad applicability in pediatric oncology. Given the ongoing clinical trials for CLR 131 in adults, these data support the development of pediatric clinical trials and provide detailed dosimetry that may lead to improved MRT treatment planning.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Marsh IR, Grudzinski J, Baiu DC, et al. Preclinical Pharmacokinetics and Dosimetry Studies of 124I/131I-CLR1404 for Treatment of Pediatric Solid Tumors in Murine Xenograft Models. J Nucl Med. 2019. PMID: 30926646. doi:10.2967/jnumed.118.225409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。